Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| B-Cell Chronic Lymphocytic Leukemia Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for B-Cell Chronic Lymphocytic Leukemia Overview | 11 | 1 |
| Pipeline Products for B-Cell Chronic Lymphocytic Leukemia Comparative Analysis | 12 | 1 |
| B-Cell Chronic Lymphocytic Leukemia Therapeutics under Development by Companies | 13 | 2 |
| B-Cell Chronic Lymphocytic Leukemia Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| B-Cell Chronic Lymphocytic Leukemia Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| B-Cell Chronic Lymphocytic Leukemia Products under Development by Companies | 19 | 2 |
| B-Cell Chronic Lymphocytic Leukemia Products under Investigation by Universities/Institutes | 21 | 1 |
| B-Cell Chronic Lymphocytic Leukemia Companies Involved in Therapeutics Development | 22 | 24 |
| AB Science SA | 22 | 1 |
| Aduro BioTech, Inc. | 23 | 1 |
| Amgen Inc. | 24 | 1 |
| Celgene Corporation | 25 | 1 |
| Cell Source, Inc. | 26 | 1 |
| Dynavax Technologies Corporation | 27 | 1 |
| Eisai Co., Ltd. | 28 | 1 |
| Elsalys Biotech SAS | 29 | 1 |
| F. Hoffmann-La Roche Ltd. | 30 | 1 |
| iDD biotech SAS | 31 | 1 |
| Immunomedics, Inc. | 32 | 1 |
| Johnson &Johnson | 33 | 1 |
| Juno Therapeutics Inc. | 34 | 1 |
| Lymphocyte Activation Technologies, S.A. | 35 | 1 |
| MedImmune, LLC | 36 | 1 |
| MEI Pharma, Inc. | 37 | 1 |
| Millennium Pharmaceuticals Inc | 38 | 1 |
| Molecular Templates Inc. | 39 | 1 |
| Noxxon Pharma AG | 40 | 1 |
| Ono Pharmaceutical Co., Ltd. | 41 | 1 |
| Regeneron Pharmaceuticals Inc | 42 | 1 |
| Sunesis Pharmaceuticals, Inc. | 43 | 1 |
| TheraMAB LLC | 44 | 1 |
| Unum Therapeutics, Inc. | 45 | 1 |
| B-Cell Chronic Lymphocytic Leukemia Therapeutics Assessment | 46 | 10 |
| Assessment by Monotherapy Products | 46 | 1 |
| Assessment by Combination Products | 47 | 1 |
| Assessment by Target | 48 | 2 |
| Assessment by Mechanism of Action | 50 | 2 |
| Assessment by Route of Administration | 52 | 2 |
| Assessment by Molecule Type | 54 | 2 |
| Drug Profiles | 56 | 85 |
| 202-b Drug Profile | 56 | 2 |
| AB-8779 Drug Profile | 58 | 1 |
| alemtuzumab biosimilar Drug Profile | 59 | 1 |
| alisertib Drug Profile | 60 | 5 |
| AMG-319 Drug Profile | 65 | 2 |
| BB-001 Drug Profile | 67 | 1 |
| BION-1301 Drug Profile | 68 | 1 |
| Cellular Immunotherapy for Chronic Lymphocytic Leukaemia Drug Profile | 69 | 1 |
| Cellular Immunotherapy for Hematological Malignancies Drug Profile | 70 | 1 |
| Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies Drug Profile | 71 | 2 |
| Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies Drug Profile | 73 | 2 |
| Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies Drug Profile | 75 | 2 |
| Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia Drug Profile | 77 | 1 |
| Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia Drug Profile | 78 | 1 |
| Cellular Immunotherapy to Target CD19 for B-Cell Malignancies Drug Profile | 79 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 80 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 81 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 82 | 1 |
| durvalumab Drug Profile | 83 | 10 |
| E-7449 Drug Profile | 93 | 1 |
| IDD-001 Drug Profile | 94 | 1 |
| IDD-002 Drug Profile | 95 | 1 |
| JNJ-64052781 Drug Profile | 96 | 2 |
| lenalidomide Drug Profile | 98 | 14 |
| MAT-303 Drug Profile | 112 | 1 |
| ME-401 Drug Profile | 113 | 2 |
| mRNA ACTR + rituximab Drug Profile | 115 | 2 |
| MT-3724 Drug Profile | 117 | 2 |
| olaptesed pegol Drug Profile | 119 | 4 |
| ONO-4059 Drug Profile | 123 | 2 |
| REGN-1979 Drug Profile | 125 | 1 |
| SD-101 Drug Profile | 126 | 3 |
| SNS-062 Drug Profile | 129 | 2 |
| TAB-08 Drug Profile | 131 | 2 |
| tocilizumab Drug Profile | 133 | 8 |
| B-Cell Chronic Lymphocytic Leukemia Dormant Projects | 141 | 3 |
| B-Cell Chronic Lymphocytic Leukemia Discontinued Products | 144 | 1 |
| B-Cell Chronic Lymphocytic Leukemia Product Development Milestones | 145 | 1 |
| Featured News &Press Releases | 145 | 1 |
| Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement | 145 | 1 |
| Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia | 145 | 1 |
| Appendix | 146 | 2 |
| Methodology | 146 | 1 |
| Coverage | 146 | 1 |
| Secondary Research | 146 | 1 |
| Primary Research | 146 | 1 |
| Expert Panel Validation | 146 | 1 |
| Contact Us | 146 | 1 |
| Disclaimer | 147 | 1 |